바로가기 메뉴
컨텐츠바로가기
주메뉴바로가기
하단메뉴바로가기

Market Research Report

Market Research Report

Hemostat Market in Korea 2020
2020.04139 pagesID: 20190001Format: PDF

Copyright© 2019 Synex Consulting Ltd., All rights reserved.

In 2018, the local hemostatic market in Korea is estimated to have reached US$*** Million based on initial supply price and US$*** Million based on end user (medical institution) purchase price.

Korean hemostatic market is expected to grow at an average annual rate of ***% over the next five years since 2019. In 2023, the market is expected to reach US$*** Million based on the initial supply price and US$*** Million based on the final purchase price of medical institution users.

In 2018, about US$ *** million (***%) out of US$*** Million was paid and reimbursed from National Health Insurance Service (NHIS) health insurance benefits, whereas it is estimated that the remaining US$*** million (***%) was paid by patients themselves. This is because NHIS does not pay whole price of local hemostats used per surgery where the remains should be paid by patient as out-of-pocket.

In 2018, the total reimbursement of local hemostats was US$*** million. The surgical hemostats pharmaceuticals reimbursement was US$12.9 million (***%), surgical hemostats medical device was US$*** million(***%), post vascular intervention surgeries medical device reimbursement was about US$*** billion (***%). In 2018, health insurance benefits reimbursed for local hemostats grew ***% to US$*** from previous year. In 2016, the reimbursement grew from US$*** million to an annual average of ***% for two years.

In 2019, the local hemostat market is expected to grow ***% from 2018, reaching around US$*** million based on initial supply price and US$*** million based on medical institution purchase prices. Of these, the health insurance reimbursement size is estimated US$*** million.

According to the reimbursement size of surgical hemostats by department category in 2018, neurosurgery department were US$*** million, which consisted highest portion of ***% of the total reimbursement for local hemostat of US$*** million, followed by general surgery US$*** million(***%), thoracic surgery US$*** million(***%).

According to the reimbursement size of surgical hemostats by end user category in 2018, teritary hospital were US$*** million, which consisted highest portion of ***% of the total reimbursement for local hemostat of US$*** million, followed by general hospital US$***million(***%), hospital US$*** million(***%).

In 2018, *** manufacturers / importers registered about *** products in the health insurance. In local hemostatic market, 11 major suppliers are Baxter, Hyundai Pharmaceutical, GC Pharma, Johnson& Johnson Medical, DalimTissen, Hanmi Healthcare, Samyang Biopharm, Bard Korea, Curesys, Nano Pharm, and SK Plasma. (Based on listed product code in`Therapeutic products Reimbursement/Non-Reimbursement List and Maximum Cap Price Table')

Among the top three suppliers (Baxter, Hyundai Pharmaceutical, and GC Pharma), their total market share was ***% of the total, and it is estimated that the remaining *** suppliers accounted for ***% of the market. In the local hemostatic market, each of the top three companies, Baxter's (Floseal, Tiseal and HemoPatch) account for ***%, Hyundai's (Tachosil) ***%, and GC's (Greenplast) ***%.

Product ingredients can be classified into oxidized regenerated cellulose (ORC), gelatin, collagen, mixed ingredients and materials, and others. Accordingly, each hemostat suppliers distribute various products consisting different product forms and ingredients according to the needs of customers with differentiating sales and marketing strategies.

In the 1990s, AviteneTM and SURGICEL products paved the way for the foundation of local hemostatic drug products market. Since 2017, the number of suppliers and product diversification continues as the national health insurance system has expanded the reimbursement criteria for local hemostatic approved as medical devices. The local hemostat market has been continuously grown due to health insurance coverage expansion policies and it is expected that this direction is expected to continue.

Korean hemostat market is expected to grow at an annual average of ***% over the next five years, driven by the increase in aging population, the number of surgery, the number of endoscopic surgery, the number of robotic surgery, the number of cancer patients, the trauma center, and the number of foreign patients. On the other hand, the health insurance pricing decision method based on the mechanism of action, shape, size, etc. of the product, is expected to suppress the distribution of hemostats with various materials and effects. In addition, local hemostatic agents are divided into Diagnostic Related Group (DRG) and new Diagnostic Related Group (nDRG) materials. Therefore, the government's policy in relation to expanding and applying DRG and nDRG will act as a restrain factor for the use of hemosts and its market growth.

The product preference has accumulated over a long period of time since the use of the hemosts, thus, it is difficult to expect a abrupt change in a short period of time. However, in order to provide quality medical services, there still remains high interest, potential demands, and unmet needs for hemostats with proven effectiveness and safety. Therefore, there are still opportunities for growth in new products that fulfills user friendliness, improve preparation time, cost, and effectiveness.

GLOSSARYOF TERMS,ABBREVIATIONS, AND ACRONYMS


CH 1. INTRODUCTION
1.1 Purpose
1.2 Utilization of Benefits
1.3 Scope
1.4 Market Segementation
1.5 Terminology
1.6 Research Methods
1.6.1 Secondary Research
1.6.2 Primary Research
1.7 Analysis and Estimateion Methods
1.7.1 Market Size Price Standard by Data Source
1.7.2 Exchange Rate
1.7.3 Market Size Estimation Methods
1.7.3.1 Reimbursement Size Estimation Methods

CH 2. EXECUTIVE SUMMARY

CH 3. MARKET OVERVIEW
3.1 Total Market
3.1.1 5-YearForecast
3.2 Use Volume of Hemostats by Medical Institutions
3.2.1 Total Hemostats Product Market
3.2.2 Surgeries, Hemostats Product Market
3.2.2.1 Hemostats Product Market, By Medical Department
3.2.2.2 Hemostats Product Market, By End User Type
3.2.3 Postoperative Vascular Intervention Hemostats Product Marke

CH 4. MAJOR SUPPLIERS STATUS
4.1 Baxter
4.2 Hyundai pharm
4.3 GC Pharma
4.4 Johnson & Johnson Medical Korea Ltd
4.5 Dalim Tissen Co.,Ltd
4.6 Hanmi Healthcare Inc
4.7 Samyang Biopharm
4.8 Bard Korea Ltd
4.9 Curesys
4.10 Nano Pharm
4.11 SK Plasma Co., Ltd.

CH 5. MARKET DYNAMICS
5.1 Health care Key Indicators in Korea
5.1.1 Historical Overview and Prospect of Market Development
5.1.2 Historical Overview of Payment Environment
5.1.3 Number of Medical Institutions in Korea
5.1.4 Reimbursement and Non-Reimbursement Classifications of Hemostats
5.2 Recent trends in key indicators of Hemostats Market Size
5.2.1 Aging Population
5.2.2 Number of Surgical Procedures>
5.2.3 Number of Endoscopic Surgery
5.2.4 Number of Robotic Surgery
5.2.5 Number of Cancer Patients
5.2.6 Trauma Center
5.2.7 Number of Foreign Patients
5.3 Market Drivers
5.3.1 Main Indicator
5.3.2 Supply
5.4 Opportunity
5.4.1 Increasing Demand due to Increase in Number of Surgeries
5.4.2 Coverage Expansion of National Health Insurance Policy
5.4.3 Hemostats with Innovative Features
5.4.4 Clinical Study on Hemostats Treatment Technology
5.5 Threat
5.5.1 Revaluation Reimbursement Prices
5.5.2 Expansion of Diagnosis Related Group(DRG) and New Diagnosis Related Group(nDRG)
5.6 Unmet Needs


[Table 1] Hemostats Classifications
[Table 2] Korean Hemostats Market Size (2014-2018) (unit: US$1,000)
[Table 3] Korean Hemostats Market Volume Forecast (2018-2023) (Unit: US$ 1,000)
[Table 4] Reimbursement Size by Hemostats (2016-2018)
[Table 5] Reimbursement Size by Surgical Hemostats (2016-2018)
[Table 6] Quarterly Reimbursement Volume of Surgical Hemostats, by Medical Device
[Table 7] Reimbursement Volume of Surgical Hemostats, by Department Product Category (2016-2018)
[Table 8] Hemostats Sales Prospects by Major Departments
[Table 9] Surgical Hemostats Market, By End User Type (2016-2018)
[Table 10] Reimbursement Volume by Postoperative Vascular Intervention Hemostats (2016-2018)
[Table 11] Manufacturers and Suppliers, by Major Brands
[Table 12] Major Brands Suppliers Market Share Estimation (2018)
[Table 13] Product Forms Supply Satus, by Major Companies (2019.12 Basis)
[Table 14] Major Ingredients and Features, by Product Forms
[Table 15] Product Ingredients Supply Satus, by Major Companies (2019.12 Basis)
[Table 16] Major Ingredients Related Product, by Major Surgeries and Bleeding Patterns
[Table 17] Baxter Main Product - Tisseel
[Table 18] Baxter Main Product - Floseal
[Table 19] Baxter Main Product – Hemo Patch
[Table 20] Hyundai Pharm Main Product – Tachosil®
[Table 21] GC Pharma Main Product – Greenplast-Q PFS KIT®
[Table 22] Johnson & Johnson Korea Ltd Main Product– SURGICEL®
[Table 23] Johnson & Johnson Korea Ltd Main Product– EViCEL®
[Table 24] Johnson & Johnson Korea Ltd Main Product– SPONGOSTAN®
[Table 25] Dalim Tissen Co.,Ltd Main Product - Collastat
[Table 26] Hanmi Pharmaceutical co., ltd. Main Product– Kollagen resorb
[Table 27] Samyang Biopharmaceuticals Main Product – SurgiGuard®
[Table 28] Samyang Biopharmaceuticals Main Product – Q-GuardTM
[Table 29] Bard Korea Ltd Main Product – AviteneTM
[Table 30] Bard Korea Ltd Main Product – AristaTM
[Table 31] CureSys Main Product - NOVACOL Pad
[Table 32] CureSys Main Product -NOVACOL Fibrillar®
[Table 33] CureSys Main Product - Equitamp®
[Table 34] CureSys Main Product – Cutanplast sponge
[Table 35] NanoPharm Corp. Main Product– Avitene Web
[Table 36] SK Plasma Co., Ltd. Main Product - Beriplast® P Combi-Set
[Table 37] Number of Medical Institutions in Korea (2019)
[Table 38] Reimbursement and Non-Reimbursement Classifications of Hemostats
[Table 39] Korean Population and Elderly Population of Age 65 or Over
[Table 40] Number of Surgery Claims of National Health Insurance (2014-2018)
[Table 41] Annual Number of Major Surgical Procedures (2014-2018) (Unit: Case)
[Table 42] Endoscopic Surgery Status in Korea (2014-2018)
[Table 43] Robotic Surgery Act Code, Term and Names
[Table 44] Number of Robotic Surgery in Korea (2005-2014)
[Table 45] Annual Cancer Categorized Patients Status (2013-2018)
[Table 46] Trauma Center Status (2014-2018)
[Table 47] Trauma Center Detailed Status
[Table 48] Foreign Patient Status (2014-2018)
[Table 49] Foreign Patients Visit Status by Departments (2014-2018)
[Table 50] Summary of Market Drivers
[Table 51] Number of Hemostats Listed for Reimbursement (Unit: Case)
[Table 52] Reimbursement Criteria by Hemostats
[Table 53] Hemostats Clinical Trial Approval Status (2016-2020) (2020.01.08 Basis)
[Table 54] Absorbable Hemostats Products Classification and Maximum Cap Price Reference Amount
[Table 55] Korean Diagnostic Related Group Claims Status (2014-2018)
[Fig 1] Hemostats Initial Supply Volume in Korea (unit: US$1,000)
[Fig 2] Hemostats Supply Volume in Korea (2014-2018) (unit: US$1,000)
[Fig 3] Korean Hemostats Market Sales Forecast (2018-2023) (Unit: US$ 1,000)
[Fig 4] Use Volume of Hemostats by Medical Institutions (2018)
[Fig 5] Use Volume of Hemostats Market Sales Forecast of Medical Institutions (2019-2023)
[Fig 6] Reimbursement Volume by Hemostats Product Category (2016-2018)
[Fig 7] Reimbursement Volume by Surgical Hemostats Product Category (2016-2018)
[Fig 8] Surgical Hemostats Market, By Medical Department (2018)
[Fig 9] Surgical Hemostats Market, By Medical Department (2016-2018)
[Fig 10] Surgical Hemostats Market, By End User Type (2018)
[Fig 11] Surgical Hemostats Market, By End User Type (2016-2018)
[Fig 12] Reimbursement Volume by Postoperative Vascular Intervention Hemostats (2016-2018)
[Fig 13] Sales Volume of Korean Hemostats Distributors Market Share Estimation (2018)
[Fig 14] Elderly Age 65 or Over Populations (2005-2014) (Unit: million)
[Fig 15] Number of National Health Insurance Claims for Surgical Procedures (2014-2018) (Unit: Case)
[Fig 16] Number of Endoscopic Surgery Patients (2014-2018)
[Fig 17] Number of Robotic Surgery (2005-2014) (Unit: Case)
[Fig 18] Number of Foreign Patients (2014-2018)
[Fig 19] Number of Reimbursement Claim Numbers and Reimubrsement Size of Diagnosis Related Group (DRG) and New Diagnosis Related Group,(nDRG) (Unit: US$ 1,000)
[Fig 20] Unmet Needs of Korean Hemostats Market

Baxter
Hyundai pharm
Green Cross Corp
Johnson& Johnson Medical
DalimTissen
Hanmi Healthcare
Samyang Biopharm
Bard Korea
Curesys
Nano Pharm
SK Plasma
Cardical Health Korea
Abbott Korea Limited
Terumo Korea Corporation Co.,LTD.

US$ 2,500 (excluded VAT)


_